SFT2D2 (SFT2 domain containing 2) is a membrane-associated protein involved in vesicular trafficking and cellular homeostasis. Based on functional studies, SFT2D2 plays a role in endosome-to-Golgi retrieval, a critical membrane trafficking pathway 1. The protein contains extracellular exosome localization and exhibits protein-binding capacity [GO annotations provided]. In disease contexts, SFT2D2 has emerged as a functionally significant gene in multiple pathological conditions. A chimeric SFT2D2-TBX19 transcript promotes prostate cancer progression by encoding the TBX19-202 protein and stabilizing mitochondrial ATP synthase through ATP5F1A phosphorylation, enhancing ATP production and supporting cancer cell proliferation even under mitochondrial stress 2. Anti-SFT2D2 autoantibodies contribute to psychotic behavior in mice with compromised blood-brain barrier by activating glial cells, reducing dendritic spine density, and increasing complement molecule C4 expression, suggesting involvement in synaptic plasticity 3. SFT2D2 was identified as part of a 15-gene signature predicting bone metastasis in breast cancer with 81.2% accuracy in independent validation 4, and appears dysregulated in triple-negative breast cancer as a potential biomarker 5. Additionally, SFT2D2 expression is significantly decreased in Parkinson's disease patients, implicating it in neurodegeneration 6. These findings establish SFT2D2 as a pleiotropic gene with roles in normal trafficking and disease-associated pathways.